Study of 4 refractory juvenile dermatomyositis (6-20yrs) treated with baricitinib (4–8 mg/day) Significant improvement noted by week 4 in global activity, skin scores, weakness but little change in muscle enzymes or calcinosis. Steroids/other meds lowered https://t.co/GKGBXrogEm